UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000012874 |
|---|---|
| Receipt number | R000015038 |
| Scientific Title | Prospective multicenter clinical study on outcome measures for HTLV-1-associated myelopathy (HAM) |
| Date of disclosure of the study information | 2014/01/16 |
| Last modified on | 2021/01/22 09:24:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Prospective multicenter clinical study on outcome measures for HTLV-1-associated myelopathy (HAM)
Acronym
HAM-OM
Scientific Title
Prospective multicenter clinical study on outcome measures for HTLV-1-associated myelopathy (HAM)
Scientific Title:Acronym
HAM-OM
Region
| Japan |
Condition
Condition
HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)
Classification by specialty
| Neurology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
In order to develop outcome measures for evaluating HAM, data on candidate biomarkers and clinical parameters is gathered from multiple institutions, and biostatistical analysis is performed to evaluate the adequacy of the candidates as biomarkers and outcome measures. Prognostic biomarkers are identified by gathering HAM patient-derived bioresources before and after treatment, measuring the levels of prognostic biomarkers that have already been reported, analyzing with OMICS, and evaluating the degree of correlation between these levels and disease progression. Furthermore, changes in candidate biomarker levels due to treatment are analyzed to investigate their usefulness as surrogate/predictive biomarkers of treatment effectiveness.
Basic objectives2
Others
Basic objectives -Others
Search for prognostic biomarkers and clinical outcome measures
Trial characteristics_1
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Motor impairment severity, time for 10 meter walk, distance walked in 2 minutes
1) Blood and CSF<Blood>Serum concentrations of sIL-2R, CXCL10, and CXCL9; HTLV-1 proviral load in PBMCs
<CSF>Cell count, anti-HTLV-1 antibody titer, neopterin, CXCL9, CXCL10, CXCL13, HTLV-1 proviral load in cells in the CSF
2) Proteomic analysis of the plasma and CSF 3) Whole genomic analysis of PBMC-derived DNA, copy number variation analysis, peripheral blood RNA expression analysis
Key secondary outcomes
4) Treatment contents
5) QOL indicators
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.Patients diagnosed with HAM according to the WHO guidelines (Kagoshima Science Council 1988)
2.The patient truly consents to participate in the study of his or her own free will (in the case of minors, requires consent of the legal guardian)
Key exclusion criteria
1. Patients with spinal cord compression lesion complications such as from cervical spine disease,intervertebral disc herniation, or yellow ligament ossification that affect gait assessment
2. Patients with knee or hip osteoarthritis, rheumatoid arthritis, or another musculoskeletal disease that affects gait assessment
3. Patients with Parkinsons disease or the aftereffects of stroke, cerebral hemorrhage, subarachnoid hemorrhage or other neurological disturbance affecting gait assessment
4. Serious complications that affect gait assessment (heart failure, respiratory dysfunction, renal failure, liver failure, etc.)
5. Patients with mental disorders such as dementia or neuropsychiatric diseases that affect ability to answer interview questions
6. Patients with any disease other than HAM for which they might be prescribed steroids (excluding topic medicines), interferon, or anti-cancer drugs
7. Patients with both severe anemia (hemoglobin less than 9.0 g/dl) and intracranial hypotension syndrome from whom it is deemed unwise with regard to the subjects safety to collect blood or CSF samples
8. Patients who have been deemed unfit for the study by a study investigator or physician.
Target sample size
150
Research contact person
Name of lead principal investigator
| 1st name | Yoshihisa |
| Middle name | |
| Last name | Yamano |
Organization
St. Marianna University School of Medicine
Division name
Division of Neurology, Department of Internal Medicine
Zip code
2168511
Address
2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan
TEL
044-977-8111
yyamano@marianna-u.ac.jp
Public contact
Name of contact person
| 1st name | Yoshihisa |
| Middle name | |
| Last name | Yamano |
Organization
St. Marianna University School of Medicine
Division name
Division of Neurology, Department of Internal Medicine
Zip code
2168511
Address
2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan
TEL
044-977-8111
Homepage URL
yyamano@marianna-u.ac.jp
Sponsor or person
Institute
St. Marianna University
Institute
Department
Personal name
Funding Source
Organization
The Research on Measures for Intractable Diseases Project of the Ministry of Health, Labour, and Welfare
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
St. Marianna University
Address
2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan
Tel
044-977-8111
k-sienbu.mail@marianna-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
聖マリアンナ医科大学（神奈川県）
国立病院機構 北海道医療センター 神経内科（北海道）
東北大学病院 神経内科、多発性硬化症治療学寄付講座（宮城県）
京都府立医科大学附属北部医療センター（京都府）
京都府立医科大学大学院 神経内科学（京都府）
関西医科大学附属枚方病院（大阪府）
川崎医科大学病院 神経内科・微生物学（岡山県）
愛媛大学医学部附属病院 薬物療法・神経内科（愛媛県）
九州大学病院 神経内科（福岡県）
長崎大学病院 神経内科（長崎県）
大分県立病院 神経内科（大分県）
鹿児島大学大学院医歯学総合研究科神経病学講座 神経内科・老年病学分野（鹿児島県）
医療法人三州会 大勝病院 神経内科（鹿児島県）
琉球大学医学部付属病院 神経内科（沖縄県）
湘陽かしわ台病院（神奈川県）
やまのクリニック（鹿児島県）
霞が関アーバンクリニック（東京都）
岩手医科大学内科学講座 神経内科・老年科分野（岩手県）
福岡大学医学部 神経内科学（福岡県）
岩手県立大船渡病院 神経内科（岩手県）
岩手県立久慈病院 神経内科（岩手県）
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 01 | Month | 16 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2013 | Year | 10 | Month | 21 | Day |
Date of IRB
| 2014 | Year | 01 | Month | 14 | Day |
Anticipated trial start date
| 2014 | Year | 01 | Month | 14 | Day |
Last follow-up date
| 2024 | Year | 01 | Month | 13 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Prospective multicenter clinical study
Management information
Registered date
| 2014 | Year | 01 | Month | 16 | Day |
Last modified on
| 2021 | Year | 01 | Month | 22 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015038
